Catabasis Pharma rises after RA Capital discloses 7.5% passive stake

Astria Therapeutics

15/06/2021 22:34

** Shares of drug developer  CATB.O  up 38.7% at $2.83 in
extended trade - their highest in more than 2 months
    ** Stock is second biggest pct gainers across U.S. exchanges
after the bell
    **  Investment manager RA Capital Management LP discloses
7.5% passive stake in CATB as of June 8 - SEC filing (https://bit.ly/3zwP4je)
    ** CATB's lead candidate is QLS-215, a monoclonal antibody 
designed to treat Hereditary Angioedema - a genetic disorder
    ** Stock had fallen 4.7% YTD up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))